Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PULM
Upturn stock ratingUpturn stock rating

Pulmatrix Inc (PULM)

Upturn stock ratingUpturn stock rating
$7
Last Close (24-hour delay)
Profit since last BUY-22.44%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: PULM (1-star) is a SELL. SELL since 4 days. Profits (-22.44%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10Target price
Low$1.78
Current$7
high$10.4

Analysis of Past Performance

Type Stock
Historic Profit -25.7%
Avg. Invested days 33
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 25.57M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 1
Beta 1.45
52 Weeks Range 1.78 - 10.40
Updated Date 06/30/2025
52 Weeks Range 1.78 - 10.40
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.35

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -506.98%

Management Effectiveness

Return on Assets (TTM) -31.67%
Return on Equity (TTM) -93.19%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 16044995
Price to Sales(TTM) 13.31
Enterprise Value 16044995
Price to Sales(TTM) 13.31
Enterprise Value to Revenue 8.35
Enterprise Value to EBITDA 1.57
Shares Outstanding 3652280
Shares Floating 3628107
Shares Outstanding 3652280
Shares Floating 3628107
Percent Insiders 0.66
Percent Institutions 8.81

Analyst Ratings

Rating 1
Target Price 10
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Pulmatrix Inc

stock logo

Company Overview

overview logo History and Background

Pulmatrix Inc. was founded in 2003. It is a biopharmaceutical company focused on developing inhaled therapies to prevent and treat respiratory diseases. It has transitioned from a broader respiratory focus to concentrating on severe asthma and fungal infections.

business area logo Core Business Areas

  • iSPERSE Technology: Pulmatrix's proprietary iSPERSE technology enables the delivery of small and large molecules directly to the lungs via dry powder formulations, enhancing efficacy and reducing systemic side effects.
  • Pulmazole: An inhaled formulation of itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. Currently in clinical development.
  • PUR1900: A pipeline product currently in preclinical development. It is a narrow spectrum kinase inhibitor targeting neutrophilic asthma.

leadership logo Leadership and Structure

The leadership team includes highly experienced professionals in drug development, finance, and management. The organizational structure includes research & development, clinical operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • Pulmazole: Pulmazole is Pulmatrix's lead product candidate for treating ABPA. Currently in Phase 3 clinical trials. Market share data is not available yet. Potential competitors include oral itraconazole formulations and other antifungal treatments, such as those by Viatris (MYL) and Teva (TEVA).
  • iSPERSE Technology: Pulmatrix licenses its iSPERSE technology to other pharmaceutical companies for use in their inhaled drug products. No direct revenue available. Competitors include other drug delivery technologies and companies like MannKind (MNKD) which specialize in inhaled product technologies.

Market Dynamics

industry overview logo Industry Overview

The respiratory drug market is substantial and growing, driven by increasing prevalence of asthma, COPD, and fungal infections. There is a high demand for targeted drug delivery systems to improve efficacy and reduce systemic side effects. The market is competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.

Positioning

Pulmatrix is positioned as a specialty pharmaceutical company with a focus on inhaled therapies. Its proprietary iSPERSE technology provides a competitive advantage by enabling efficient delivery of drugs directly to the lungs. Their Pulmazole targets a specific niche within the larger asthma and antifungal market.

Total Addressable Market (TAM)

The TAM for ABPA treatment is estimated to be in the hundreds of millions of dollars globally. Pulmatrix is positioned to capture a portion of this market with Pulmazole, if approved. The TAM for iSPERSE is harder to quanify as it is tied to the value of the new drugs it enables.

Upturn SWOT Analysis

Strengths

  • Proprietary iSPERSE technology
  • Targeted drug delivery
  • Lead product in Phase 3 clinical trials
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial success
  • Single lead product candidate
  • Relatively small market capitalization

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of iSPERSE technology applications
  • Regulatory approval and commercialization of Pulmazole
  • Development of new inhaled therapies

Threats

  • Clinical trial failures
  • Competition from existing treatments
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • MYL
  • TEVA
  • MNKD
  • GILD

Competitive Landscape

Pulmatrix's iSPERSE technology and focus on inhaled therapies differentiate it from larger pharmaceutical companies. However, it faces competition from companies with established products and greater financial resources. Its ability to secure partnerships will be crucial for long-term success.

Growth Trajectory and Initiatives

Historical Growth: Pulmatrix's growth has been driven by advancements in its clinical programs and strategic partnerships. The past few years have seen a shift to focus on Pulmazole. There has been moderate growth in R&D investments.

Future Projections: Future growth is dependent on the success of Pulmazole's clinical trials and eventual commercialization. Analyst estimates vary, but project substantial revenue growth if Pulmazole is approved.

Recent Initiatives: Focus on advancing Pulmazole through Phase 3 clinical trials. Seeking strategic partnerships to support commercialization. Continued investment in research and development of iSPERSE technology.

Summary

Pulmatrix is a biopharmaceutical company with promising iSPERSE technology and a lead product, Pulmazole, in late-stage development. The company's future hinges on the success of Pulmazole, and it faces challenges related to funding and competition. Strategic partnerships and further development of its technology are essential for growth. Financial resources are tight and should be managed well.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Pulmatrix Inc. Investor Relations
  • SEC Filings
  • Analyst Reports
  • Industry Publications
  • Corporate press releases

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data may be estimated and is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pulmatrix Inc

Exchange NASDAQ
Headquaters Framingham, MA, United States
IPO Launch date 2014-03-21
Interim CEO & Interim CFO Mr. Peter Ludlum CMA, MBA
Sector Healthcare
Industry Biotechnology
Full time employees 2
Full time employees 2

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.